On June 30, 2025, Opus Genetics, Inc. announced that it granted equity awards to two new non-executive employees as a material inducement to employment. These awards were approved by the Compensation Committee of the Board of Directors under the company’s 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards consisted of stock options to purchase an aggregate of 240,000 shares of the company’s common stock and 150,000 restricted stock units (RSUs). The stock options have an exercise price of $0.94, equal to the closing price on the grant date.
The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder in quarterly installments. The RSUs vest in four equal installments on the first, second, third, and fourth anniversaries of the grant date, contingent on continued employment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.